ACP
VRDN icon

Acuta Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

Acuta Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-199,433
Closed -$2.59M – 49
2024
Q2 		$2.59M Hold
199,433
– – 2.19% 18
2024
Q1 		$3.49M Sell
199,433
-82,067
-29% -$1.59M 2.27% 18
2023
Q4 		$6.13M Buy
281,500
+57,161
+25% +$902K 3.45% 11
2023
Q3 		$3.44M Sell
224,339
-368
-0.2% -$7.02K 2.31% 17
2023
Q2 		$5.35M Buy
224,707
+56,707
+34% +$1.45M 3.62% 9
2023
Q1 		$4.27M Sell
168,000
-228,500
-58% -$7.33M 3.15% 15
2022
Q4 		$11.6M Buy
396,500
+33,765
+9% +$778K 7.13% 2
2022
Q3 		$7.44M Buy
362,735
+128,709
+55% +$2.31M 3.2% 10
2022
Q2 		$2.71M Sell
234,026
-105,974
-31% -$1.42M 1.51% 22
2022
Q1 		$6.29M Buy
340,000
+22,000
+7% +$423K 2.94% 11
2021
Q4 		$6.29M Buy
318,000
+182,193
+134% +$3.39M 2.64% 13
2021
Q3 		$2.23M Buy
+135,807
New +$1.99M 0.79% 33

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Acuta Capital Partners's VRDN Position: Q3 2024 in Review

Acuta Capital Partners sold out of Viridian Therapeutics (VRDN) in Q3 2024, closing a stake of 199,433 shares — an estimated $2.59M sold.

Acuta Capital Partners first reported a position in VRDN in Q3 2021 and held it in 12 quarters. The position peaked at $11.6M in Q4 2022. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Acuta Capital Partners reported no remaining Viridian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 199,433 Viridian Therapeutics shares in Q3 2024, an estimated $2.59M.
  • Acuta Capital Partners first reported a position in Viridian Therapeutics in Q3 2021 and held it in 12 quarters.
  • Acuta Capital Partners's Viridian Therapeutics position peaked at $11.6M in Q4 2022.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.